Log In
BCIQ
Print this Print this
 

Pimasertib (AS 703026, AS703026, MSC1936369B)

  Manage Alerts
Collapse Summary General Information
Company Merck KGaA
DescriptionInhibitor of MEK1 and MEK2
Molecular Target MAP kinase kinase 1 (MAP2K1) (MEK1) ; MAP kinase kinase 2 (MAP2K2) (MEK2)
Mechanism of ActionMEK inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMelanoma
Indication DetailsTreat malignant melanoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/20/2010

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today